Recent advances in the synthesis of boron-stereogenic compounds
Beilstein Journal of Organic Chemistry · 19.11.2026 · 22 · 1715-1739
DOI: 10.3762/bjoc.22.139 ↗Kurz gefasst
Fachartikel in der Zeitschrift Beilstein Journal of Organic Chemistry, online erschienen am 19.11.2026. Verfasst von Yongke Wang und 2 weiteren Autor:innen. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Tetracoordinate boron species represent a vital class of compounds in organoboron chemistry. Owing to their unique structural features and outstanding optoelectronic properties, they exhibit broad application potential in chemical synthesis, biomedicine, and materials engineering. However, systematic synthetic protocols for chiral tetracoordinate boron complexes remain scarce. Herein, we review recent advances in the construction of stereogenic tetracoordinate boron centers, organizing catalytic approaches into six classes according to the catalyst type: copper, palladium, rhodium, nickel/cobalt, organocatalysis, and phase-transfer catalysis. The transformations covered include desymmetrization, kinetic resolution, direct asymmetric B(sp 2 )-to-B(sp 3 ) conversion, and chirality transfer. This overview aims to inspire further development of efficient routes to chiral tetracoordinate boron compounds.
Zitieren
APA
Wang, Y., Tian, S., & Zhang, W. (2026). Recent advances in the synthesis of boron-stereogenic compounds. Beilstein Journal of Organic Chemistry, 22, 1715-1739. https://doi.org/10.3762/bjoc.22.139
Vancouver
Wang Y, Tian S, Zhang W. Recent advances in the synthesis of boron-stereogenic compounds. Beilstein Journal of Organic Chemistry. 2026;22:1715-1739. doi:10.3762/bjoc.22.139
BibTeX
@article{Wang2026,
author = {Wang, Yongke and Tian, Sichao and Zhang, Weidong},
title = {Recent advances in the synthesis of boron-stereogenic compounds},
journal = {Beilstein Journal of Organic Chemistry},
year = {2026},
volume = {22},
pages = {1715--1739},
doi = {10.3762/bjoc.22.139}
}
EUVIMED